Análisis y diagnóstico genético, cáncer hereditario

 

CHIMERA Pharma is managed at a corporate level by the BIONOSTRA Group and also incorporates experienced management in the area of immunology and vaccine development:

bionostra Santiago Gimeno de Priede - President

Founder of Bionostra Group. BSc in Biological Sciences and journalist. Founder and President of Bioalma (www.bioalma.com), and Founder and President of Microbionta (www.microbionta.com) Member of the ASEBIO board of directors (Spanish Biotech Entrepreneurs Association).
 

bionostra Juan Carlos del Castillo Tamayo - Chief Exec.Officer

BSc in Economics. Manager of Centro Nacional de Biotecnología (Spain). Founder and General Manager of the Bionostra Group. Founder and CEO of Bioalma SL (www.bioalma.com), Founder and CEO of Microbionta SL (www.microbionta.com).

bionostra Thomas Zürcher - R&D Director

PhD at the Institute for Immunology and Virology, Univ. of Zürich and postdoctoral at Mount Sinai School of Medicine (NY) and the Centro Nacional de Biotecnología (Spain). Clinical and Molecular Virology Group Leader for 7 years at GlaxoSmithKline (UK).

bionostra Cayetano von Kobbe - Group Leader Therapeutic Vaccines

PhD in inmunology and oncology at Centro Nacional de Biotecnología (Spain) and 7-year postdoctoral at Univ. of Geneva (Switzerland) and the National Institutes of Health (US). Ramon y Cajal Researcher at Centro Nacional Investig. Oncológicas (Spain).

bionostra Juan Jose Bernal - Group Leader Prophylactic Vaccines

PhD at ETSI Agronomos Polytech. Univ. (Spain) and 3-year postdoctoral at Centro Nacional de Biotecnología (Spain) and The Samuel Roberts Noble Foundation Ardmore (US). Researcher and group leader in Bionostra group since 2000.
© Chimera Pharma S.L.U